Pregabalin controlled-release - Intellipharmaceutics

Drug Profile

Pregabalin controlled-release - Intellipharmaceutics

Alternative Names: Pregabalin extended-release; Pregabalin XR; Pregabalin XR - Intellipharmaceutics; RegabatinXR

Latest Information Update: 06 Feb 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Intellipharmaceutics International
  • Class Aminobutyric acids; Analgesics; Antiepileptic drugs; Anxiolytics; Neuroprotectants; Small molecules
  • Mechanism of Action CACNA2D1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Fibromyalgia; Neuropathic pain

Most Recent Events

  • 02 Feb 2017 Pregabalin controlled-release is still in phase I trials for Fibromyalgia and Neuropathic pain in Canada
  • 15 Mar 2016 Biomarkers information updated
  • 09 Oct 2015 Intellipharmaceutics files an IND application with FDA in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top